Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Lung Cancer | Research

Is low-dose computed tomography for lung cancer screening conveniently accessible in China? A spatial analysis based on cross-sectional survey

Authors: Jay Pan, Jianjian Wang, Wenjuan Tao, Chaohui Wang, Xiaojun Lin, Xiuli Wang, Ruicen Li

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Regular Low-Dose Computed Tomography (LDCT) for lung cancer high-risk population has been proved to improve health outcomes and relieve disease burden efficiently for both individual and society. With geographical impedance becoming the major barrier preventing patients from getting timely healthcare service, this study incorporated health seeking behavior in estimating spatial accessibility of relative scarce LDCT resource in China, thus to provide real-world evidence for future government investment and policy making.

Methods

Taking Sichuan Province in southwest China as the study area, a cross-sectional survey was first carried out to collect actual practice and preferences for seeking LDCT services. Using Computed Tomography (CT) registration data reported by owner institutions representing LDCT services capacity, and grided town-level high-risk population as demand, the Nearest Neighbor Method was then utilized to calculate spatial accessibility of LDCT services.

Results

A total of 2,529 valid questionnaires were collected, with only 34.72% of the high-risk populations (746 individuals) followed the recommended annual screening. Participants preferred to travel to municipal-level and above institutions within 60 min for LDCT services. Currently, every thousand high-risk populations own 0.0845 CT scanners in Sichuan Province, with 96.95% able to access LDCT within 60 min and over half within 15 min. Urban areas generally showed better accessibility than rural areas, and the more developed eastern regions were better than the western regions with ethnic minority clusters.

Conclusions

Spatial access to LDCT services is generally convenient in Sichuan Province, but disparity exists between different regions and population groups. Improving LDCT capacity in county-level hospitals as well as promoting health education and policy guidance to the public can optimize efficiency of existing CT resources. Implementing mobile CT services and improving rural public transportation may alleviate emerging disparities in accessing early lung cancer detection.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Chen S-M, Cao Z, Prettner K, Kuhn M, Yang J-T, Jiao L-R, Wang Z-R, Li W-M, Geldsetzer P, Bärnighausen T, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9(4):465–72.CrossRefPubMedPubMedCentral
3.
Zheng R-S, Zhang S-W, Zeng H-M, Wang S-M, Sun K-X, Chen R, Li L, Wei W-Q, He J. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2(1):1–9.CrossRef
4.
He J, Li N, Chen W-Q, Wu N, Shen H-B, Jiang Y, Li J, Wang F, Tian J-H. China guideline for the screening and early detection of lung cancer (2021, Beijing). Clin Med Chin. 2021;37(3):193–207.
5.
Oudkerk M, Liu S-Y, Heuvelmans MA, Walter JE, Field JK. Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives. Nat Rev Clin Oncol. 2021;18(3):135–51.CrossRefPubMed
6.
National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.CrossRef
7.
Jonas DE, Reuland DS, Reddy SM, Nagle M, Clark SD, Weber RP, Enyioha C, Malo TL, Brenner AT, Armstrong C, et al. Screening for lung cancer with low-dose computed tomography: updated evidence report and systematic review for the US preventive services task force. JAMA. 2021;325(10):971–87.CrossRefPubMed
8.
Lancaster HL, Heuvelmans MA, Oudkerk M. Low-dose computed tomography lung cancer screening: clinical evidence and implementation research. J Intern Med. 2022;292(1):68–80.CrossRefPubMedPubMedCentral
9.
10.
Oudkerk M, Devaraj A, Vliegenthart R, Henzler T, Prosch H, Heussel CP, Bastarrika G, Sverzellati N, Mascalchi M, Delorme S, et al. European position statement on lung cancer screening. Lancet Oncol. 2017;18(12):e754–66.CrossRefPubMed
11.
Baldwin DR, Callister ME, Guideline Development Group. The British Thoracic Society guidelines on the investigation and management of pulmonary nodules. Thorax. 2015;70(8):794–8.CrossRefPubMed
12.
US Preventive Services Task Force, Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Kubik M, et al. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(10):962–70.CrossRef
13.
Landy R, Young CD, Skarzynski M, Cheung LC, Berg CD, Rivera MP, Robbins HA, Chaturvedi AK, Katki HA. Using prediction models to reduce persistent racial and ethnic disparities in the draft 2020 USPSTF lung cancer screening guidelines. J Natl Cancer Inst. 2021;113(11):1590–4.CrossRefPubMedPubMedCentral
14.
Potter AL, Bajaj SS, Yang CJ. The 2021 USPSTF lung cancer screening guidelines: a new frontier. Lancet Respir Med. 2021;9(7):689–91.CrossRefPubMed
15.
Triplette M, Thayer JH, Pipavath SN, Crothers K. Poor uptake of lung cancer screening: opportunities for improvement. J Am Coll Radiol. 2019;16(4PtA):446–50.CrossRefPubMed
16.
Dai M, Shi J-F, Li N. Design and expected goal of cancer screening program in urban China. Chin J Prev Med. 2013;47(2):179–82.
17.
Chen W-Q, Li N, Cao M-M, Ren J-S, Shi J-F, Chen H-D, Li J, Lin C-Q, Yu X-Y, Cui H, et al. Preliminary analysis of cancer screening program in urban China from 2013 to 2017. China Cancer. 2020;29(1):1–6.
18.
Shi J, Liang D, Li D-J, Jin J, Liu Y-Y, He Y-T. Research on the screening compliance and influencing factors of cancer screening program in urban China. China Cancer. 2021;30(8):591–9.
19.
Gao Y-M, Sun X-H, Li H, Zhang H-J, Liu S-Y, Gong Q-H. Screening of lung cancer with risk assessment and CT scanning in urban residents of Ningbo City from 2013 to 2018. China Cancer. 2019;28(6):417–21.
20.
Lin Y-P, Ma J, Feng J, Zhang Q, Huang Y-C. Results of lung cancer screening among urban residents in Kunming. Chin J Lung Cancer. 2019;22(7):413–8.
21.
Song S-M, Zhou T-H, Yao F, Gu X-Y. Results of cancer screening program in urban areas of Xinjiang Uygur Autonomous Region from 2014 to 2018. China Cancer. 2022;31(9):716–22.
22.
Wang X-L, Yang H-Z, Duan Z-Q, Pan J. Spatial accessibility of primary health care in China: a case study in Sichuan Province. Soc Sci Med. 2018;209:14–24.CrossRefPubMed
23.
Xu R-H, Yue W-Z, Wei F-Y, Yang G-F, Chen Y, Pan K-X. Inequality of public facilities between urban and rural areas and its driving factors in ten cities of China. Sci Rep. 2022;12(1):13244.ADSCrossRefPubMedPubMedCentral
24.
Zhang T, Xu Y-J, Ren J-P, Sun L-Q, Liu C-J. Inequality in the distribution of health resources and health services in China: hospitals versus primary care institutions. Int J Equity Health. 2017;16(1):42.CrossRefPubMedPubMedCentral
25.
Jia P, Wang Y-F, Yang M, Wang L-M, Yang X-C, Shi X-Y, Yang L-J, Wen J, Liu Y, Yang M-K, et al. Inequalities of spatial primary healthcare accessibility in China. Soc Sci Med. 2022;314:115458.CrossRefPubMed
26.
Ji G-Y, Yang M, Li W-M. Difficulties and countermeasures of lung cancer screening. Chin J Health Manage. 2023;17(2):81–4.
27.
28.
Chen T, Pan J. The effect of spatial access to primary care on potentially avoidable hospitalizations of the elderly: evidence from Chishui City, China. Soc Indic Res. 2022;160(2):645–65.CrossRef
29.
30.
van Hulsen MAJ, Rohde KIM, van Exel J. Preferences for investment in and allocation of additional healthcare capacity. Soc Sci Med. 2023;320:115717.CrossRefPubMed
31.
Sun J, Luo H-Y. Evaluation on equality and efficiency of health resources allocation and health services utilization in China. Int J Equity Health. 2017;16(1):127.CrossRefPubMedPubMedCentral
32.
Zheng R-S, Zhang S-W, Sun K-X, Chen R, Wang S-M, Li L, Zeng H-M, Wei W-Q, He J. Cancer statistics in China, 2016. Chin J Oncol. 2023;45(3):212–20.
33.
Wang X-L, Seyler BC, Han W, Pan J. An integrated analysis of spatial access to the three-tier healthcare delivery system in China: a case study of Hainan Island. Int J Equity Health. 2021;20(1):60.CrossRefPubMedPubMedCentral
34.
Charkhchi P, Kolenic GE, Carlos RC. Access to lung cancer screening services: preliminary analysis of geographic service distribution using the ACR lung cancer screening registry. J Am Coll Radiol. 2017;14(11):1388–95.CrossRefPubMedPubMedCentral
35.
Dong T, Cheng S-W, Xu X-Y, Yuan Z-P, Deng Y. Characteristics of lung cancer incidence and mortality in Sichuan cancer registration areas from 2009 to 2017. China Cancer. 2022;31(6):437–41.
36.
Li R-C, Luo L, Tao W-J, Huang W-X, Bao T. Level of knowledge on low-dose CT lung cancer screening in Sichuan province, China: a cross-sectional study. BMJ Open. 2022;12(9):e061987.CrossRefPubMedPubMedCentral
Metadata
Title
Is low-dose computed tomography for lung cancer screening conveniently accessible in China? A spatial analysis based on cross-sectional survey
Authors
Jay Pan
Jianjian Wang
Wenjuan Tao
Chaohui Wang
Xiaojun Lin
Xiuli Wang
Ruicen Li
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12100-4

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy

Research

The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells

Study Protocol

Rational and design of prophylactic cranial irradiation (PCI) and brain MRI surveillance versus brain MRI surveillance alone in patients with limited-stage small cell lung cancer achieving complete remission (CR) of tumor after chemoradiotherapy: a multicenter prospective randomized study

Research

Physician-brief advice for promoting smoking cessation among cancer patients on treatment in low and middle-income countries: a scoping review

Research

Perioperative outcomes and continence following robotic-assisted radical cystectomy with mainz pouch II urinary diversion in patients with bladder cancer

Research

Undifferentiated sarcomatoid carcinoma of the pancreas-a single-institution experience with 23 cases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits